Medtronic: Healthy Vital Signs Heading Into Earnings

Summary:

  • Medtronic stock underperformed the market, up only 4% in the past year.
  • The options market predicts a 3.3% stock price swing post-earnings.
  • Mid-single-digit EPS growth, rising dividends, and historically high yield for Medtronic are positive factors.
  • I highlight key price levels to watch ahead of its Q1 2025 report and assess the options situation.
Medtronic office in Silicon Valley, Santa Clara, California, USA

JHVEPhoto

Medtronic (NYSE:MDT) continues to tread water as the broader market advances. The stock is up just 4% over the past 12 months, significantly underperforming the iShares U.S. Medical Devices ETF (IHI) which is higher by 10%. The Health


Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.


Leave a Reply

Your email address will not be published. Required fields are marked *